Using Workflow Modeling to Identify Areas to Improve Genetic Test Processes in the University of Maryland Translational Pharmacogenomics Project

Delivering genetic test results to clinicians is a complex process. It involves many actors and multiple steps, requiring all of these to work together in order to create an optimal course of treatment for the patient. We used information gained from focus groups in order to illustrate the current process of delivering genetic test results to clinicians. We propose a business process model and notation (BPMN) representation of this process for a Translational Pharmacogenomics Project being implemented at the University of Maryland Medical Center, so that personalized medicine program implementers can identify areas to improve genetic testing processes. We found that the current process could be improved to reduce input errors, better inform and notify clinicians about the implications of certain genetic tests, and make results more easily understood. We demonstrate our use of BPMN to improve this important clinical process for CYP2C19 genetic testing in patients undergoing invasive treatment of coronary heart disease.

[1]  J. Mega,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C19 Genotype and Clopidogrel Therapy: 2013 Update , 2013, Clinical pharmacology and therapeutics.

[2]  M. Relling,et al.  Development and use of active clinical decision support for preemptive pharmacogenomics , 2013, Journal of the American Medical Informatics Association : JAMIA.

[3]  Casey Lynnette Overby,et al.  Implementation of pharmacogenetics: The University of Maryland personalized anti‐platelet pharmacogenetics program , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.

[4]  Ching-Hon Pui,et al.  PG4KDS: A model for the clinical implementation of pre‐emptive pharmacogenetics , 2014, American journal of medical genetics. Part C, Seminars in medical genetics.

[5]  Elaine Lyon,et al.  The GeneInsight suite: a platform to support laboratory and provider use of DNA‐based genetic testing , 2011, Human mutation.

[6]  Ameen Abu-Hanna,et al.  A combined disease management and process modeling approach for assessing and improving care processes: A fall management case-study , 2013, Int. J. Medical Informatics.

[7]  Taizo Murata,et al.  Unified Modeling Language (UML) for hospital-based cancer registration processes. , 2008, Asian Pacific Journal of Cancer Prevention.

[8]  Harold Alan Pincus,et al.  User-centered design of multi-gene sequencing panel reports for clinicians , 2016, J. Biomed. Informatics.

[9]  Dean F Sittig,et al.  Notifications received by primary care practitioners in electronic health records: a taxonomy and time analysis. , 2012, The American journal of medicine.

[10]  K. Sangkuhl,et al.  Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450–2C19 (CYP2C19) Genotype and Clopidogrel Therapy , 2011, Clinical pharmacology and therapeutics.

[11]  Guilherme Del Fiol,et al.  Developing a Prototype System for Integrating Pharmacogenomics Findings into Clinical Practice , 2012, Journal of personalized medicine.

[12]  Christopher G Chute,et al.  Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. , 2014, Mayo Clinic proceedings.